Fredrik Wiklund
- Pulmonary and Respiratory Medicine top 0.5%
- Molecular Biology top 5%
- Epidemiology top 2%
- Genetics top 2%
- Oncology top 5%
- Co-authors
- Henrik GrönbergJoakim DillnerHans‐Olov AdamiPär StattinLars EgevadJianfeng XuU StendahlOlbjørn Klepp
- Topics
- Prostate Cancer Treatment and Research (52 papers)Prostate Cancer Diagnosis and Treatment (36 papers)Genetic Associations and Epidemiology (23 papers)
- Partner nations
- SwedenUnited StatesUnited Kingdom
In The Last Decade
Fredrik Wiklund
133 papers receiving 5.8k citations
Hit Papers
Peers
Comparison fields: 5 of 140
- Pulmonary and Respiratory Medicine 2.3k
- Molecular Biology 1.5k
- Epidemiology 1.1k
- Genetics 1.0k
- Oncology 907
Countries citing papers authored by Fredrik Wiklund
This map shows the geographic impact of Fredrik Wiklund's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fredrik Wiklund with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fredrik Wiklund more than expected).
Fields of papers citing papers by Fredrik Wiklund
This network shows the impact of papers produced by Fredrik Wiklund. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fredrik Wiklund. The network helps show where Fredrik Wiklund may publish in the future.
Co-authorship network of co-authors of Fredrik Wiklund
This figure shows the co-authorship network connecting the top 25 collaborators of Fredrik Wiklund. A scholar is included among the top collaborators of Fredrik Wiklund based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fredrik Wiklund. Fredrik Wiklund is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 13 | |
| 2 | 15 | |
| 3 | 3 | |
| 4 | 21 | |
| 5 | 1 | |
| 6 | 28 | |
| 7 | 93 | |
| 8 | 55 | |
| 9 | 14 | |
| 10 | 45 | |
| 11 | 36 | |
| 12 | 58 | |
| 13 | 34 | |
| 14 | 91 | |
| 15 | 79 | |
| 16 | The Chinese Equity Market : An Economic Inquiry into Investment Opportunities and Risks | 1 |
| 17 | 33 | |
| 18 | 1 | |
| 19 | 22 | |
| 20 | 66 |
About Fredrik Wiklund
Fredrik Wiklund is a scholar working on Pulmonary and Respiratory Medicine, Cancer Research and Genetics, having authored 134 papers that have together received 5.9k indexed citations. Recurring topics across this work include Prostate Cancer Treatment and Research (52 papers), Prostate Cancer Diagnosis and Treatment (36 papers) and Genetic Associations and Epidemiology (23 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (2.3k citations), Cancer Research (883 citations) and Rheumatology (699 citations). Fredrik Wiklund has collaborated with scholars based in Sweden, United States and United Kingdom. Frequent co-authors include Henrik Grönberg, Joakim Dillner, Hans‐Olov Adami, Pär Stattin, Lars Egevad, Jianfeng Xu, U Stendahl, Olbjørn Klepp, Anders Widmark and Peter Wiklund. Their work appears in journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.